Sarepta is a distressed DMD incumbent where FDA decisions on failed confirmatory data—and gene-therapy safety/competition—determine whether the stock is a renaissance rebound or a collapse.
Overview
As of January 12, 2026, Sarepta Therapeutics (SRPT) trades at **$23.83** with a market cap of roughly **$2.5B**, reflecting a company at a pivotal—and unusually fragile—moment. Sarepta has long been a leader in precision genetic medicine for Duchenne muscular dystrophy (DMD), commercializing three exon-skipping PMO therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45) and launching the flagship gene therapy ELEVIDYS in 2023 with Roche as an ex-U.S. partner. The investment case deteriorated sharply in late 2025/early 2026 due to a “perfect storm”: the FDA imposed a **boxed warning for fatal acute liver failure** on ELEVIDYS and **restricted use to ambulatory patients**, reducing addressable demand and increasing physician/payer friction; simultaneously, the **ESSENCE confirmatory trial failed** to hit statistical significance, placing the PMO accelerated approvals at real risk of withdrawal amid a tougher FDA stance (Makena/Ocaliva precedents). Financially, the company remains revenue-generating but missed expectations: preliminary **FY2025 revenue $1.86B vs. $2.12B consensus**, with ELEVIDYS adoption stalling in Q4. Sarepta still has meaningful liquidity (**~$953.8M cash**) and extended debt maturities to 2030, buying time to execute a strategic diversification into siRNA (Arrowhead partnership). The report frames SRPT as a distressed, asymmetric, and highly binary setup—potentially undervalued if therapies remain, but unsuitable for conservative capital given near-term regulatory decisions.